Skip to Main Content

Paper Details

Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.
Clin Cancer Res
27
2021
CD3, CD3+, CD68, CD68+, NAT, PD-L1, RNA, T cells, T-cell receptor, TCR, TIL, TILs, TNBC, Triple-Negative Breast Cancer, pCR, patients, programmed death-ligand 1, triple-negative breast cancer, tumor, tumor cells, tumor-infiltrating lymphocytes
Author NameAffiliation
Bora LimThe University of Texas MD Anderson Cancer Center
Naoto T UenoThe University of Texas MD Anderson Cancer Center
William F SymmansThe University of Texas MD Anderson Cancer Center
Sahil SethThe University of Texas MD Anderson Cancer Center
Sahil SethThe University of Texas MD Anderson Cancer Center
Jennifer A WargoThe University of Texas MD Anderson Cancer Center
Gabriel N HortobagyiThe University of Texas MD Anderson Cancer Center
Phillip A FutrealThe University of Texas MD Anderson Cancer Center
  • 1 - 8

Datasets

Release 1.2